Cite This Page

Jump to: navigation, search

Bibliographic details for Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib

Citation styles for Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib

APA style

Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib. (2024, January 18). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 22:14, May 5, 2024 from https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422.

MLA style

"Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 18 Jan 2024, 14:22 UTC. 5 May 2024, 22:14 <https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 18 January 2024, 14:22 UTC, <https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422> [accessed 5 May 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422 (accessed May 5, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 18, 14:22 UTC [cited 2024 May 5]. Available from: https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422.

Bluebook style

Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib, https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422 (last visited May 5, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422",
   note = "[Online; accessed 5-May-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred: 

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Scientific ramifications associated with HER2 mRNA expression as well as implicit subtype throughout refractory HER2positive stage 4 cervical cancer addressed with panHER inhibitor poziotinib --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Scientific_ramifications_associated_with_HER2_mRNA_expression_as_well_as_implicit_subtype_throughout_refractory_HER2positive_stage_4_cervical_cancer_addressed_with_panHER_inhibitor_poziotinib&oldid=563422}",
   note = "[Online; accessed 5-May-2024]"
 }


Retrieved from "https://news.npo.digital/index.php?title=Special:CiteThisPage"